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ABSTRACT
ObjeCtive
To assess whether randomised controlled trials (RCTs) 
that were registered were less likely to report positive 
study findings compared with RCTs that were not 
registered and whether the association varied by 
funding source.
Design
Cross sectional study.
stuDy sample
All primary RCTs published in December 2012 and 
indexed in PubMed by November 2013. Trial 
registration was determined based on the report of a 
trial registration number in published RCTs or the 
identification of the trial in a search of trial registries. 
Trials were separated into prospectively and 
retrospectively registered studies.
main OutCOme measure
Association between trial registration and positive 
study findings.
results
1122 eligible RCTs were identified, of which 593 
(52.9%) were registered and 529 (47.1%) were not 
registered. Overall, registration was marginally 
associated with positive study findings (adjusted risk 
ratio 0.87, 95% confidence interval 0.78 to 0.98), even 
with stratification as prospectively and retrospectively 
registered trials (0.87, 0.74 to 1.03 and 0.88, 0.78 to 
1.00, respectively). The interaction term between 
overall registration and funding source was marginally 
statistically significant and relative risk estimates were 
imprecise (0.75, 0.63 to 0.89 for non-industry funded 
and 1.03, 0.79 to 1.36 for industry funded, P 
interaction=0.046). Furthermore, a statistically 
significant interaction was not maintained in 
sensitivity analyses. Within each stratum of funding 
source, relative risk estimates were also imprecise for 
the association between positive study findings and 
prospective and retrospective registration.
COnClusiOn
Among published RCTs, there was little evidence of a 
difference in positive study findings between 
registered and non-registered clinical trials, even with 
stratification by timing of registration. Relative risk 
estimates were imprecise in subgroups of non-industry 
and industry funded trials.
Introduction
Clinical trial registration is a key method used to 
improve accountability in the conduct and reporting of 
research.1  The rationale is that transparency can be 
improved by registering the trial design in the public 
domain before reporting results. Researchers and the 
general public can then have access to a comprehensive 
list of completed and ongoing trials and can compare 
the prespecified details in the register with those in the 
published study.2 3
A small study of published reports of randomised 
controlled trials (RCTs) in cardiology showed that trials 
that were reported as registered were less likely to 
report positive study findings.4  The study was limited 
by focusing on cardiology. A meta-epidemiological 
study also found a trend towards larger treatment 
effects in trials that were not registered or were retro-
spectively registered.5  Neither study examined its 
results based on the funding source of the trial.4 5
We conducted a detailed study of primary reports of 
RCTs published in December 2012 in PubMed indexed 
journals, without restriction by journal, disease, or spe-
cialty. We sought to examine the association between 
trial registration and positive study findings and 
whether this relation varied by funding source (indus-
try versus non-industry funding).
Methods
study sample and data extraction
This analysis was part of a larger study on the epidemi-
ology and quality of reporting of RCTs4 6 7  We used a 
modified version of the Cochrane highly sensitive search 
strategy (phase 1 with added terms: “cross-over studies” 
and “multicentre study”) to identify primary reports of 
RCTs published in December 2012 and indexed in 
PubMed by 17 November 2013.8 9 The web appendix 
shows the full search strategy. RCTs were defined as pro-
spective studies that assessed healthcare interventions 
in human participants, or groups of participants, who 
WhAT IS AlReAdy knoWn on ThIS TopIC
Trial registration may be associated with positive study findings and larger 
treatment effects in randomised controlled trials
Existing studies were, however, small and did not account for important 
confounders
WhAT ThIS STudy AddS
Among published randomised controlled trials, there was little evidence of a difference 
in positive study findings between registered and non-registered clinical trials
Subgroup analyses comparing the association between trial registration and 
positive study findings in non-industry funded and industry funded clinical trials 
were inconclusive
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were randomly allocated to study interventions. We 
excluded cost effectiveness analyses, interim analyses, 
diagnostic studies, pharmacokinetic studies, pharmaco-
dynamic studies, and physiology studies.
We reviewed the titles and abstracts of retrieved records 
in duplicate. The full text of studies identified in the title 
and abstract screen were reviewed. Data extraction was 
done for general trial characteristics (number of study 
centres, study design, number of arms, and number of 
participants randomised in the trial). We also extracted 
details on funding source. Trials that were solely or par-
tially funded by commercial sources, irrespective of the 
size of the contribution, were classified as industry 
funded. In addition, if commercial sponsors provided the 
trial with an investigational agent without charge, we 
classified the trial as industry funded. This classification 
was used even if the sponsor was not involved in other 
aspects of the study. Box 1 defines the methodological 
items. A pool of eight reviewers independently extracted 
data in duplicate. Disagreements were resolved by con-
sensus or by a reviewer who did not perform the original 
extraction. We applied no language restrictions when 
conducting the search. Full texts of studies published in 
languages other than English were reviewed and 
extracted once by the same person (AJH) where possible.
exposure and outcomes
Trials were coded as registered if this was stated in the 
published study and a trial registration number was pro-
vided. As recommended during peer review, we 
 additionally searched trial registries for trials that were 
not reported as registered or did not provide a trial regis-
tration number in the published article. We searched the 
World Health Organization International Clinical Trials 
Registry Platform (WHO ICTRP), the EU Clinical Trials 
Register, clinicaltrials.gov, and the International Stan-
dard Randomised Controlled Trial Number (ISRCTN) Reg-
istry. The search was conducted using the following 
search strategy: the title of the trial; the name of the prin-
cipal investigator or a combination of keywords (eg, the 
intervention name, health condition, trial identifier), or 
both.10 We matched results in trial registries with pub-
lished articles based on the name of trial investigators, 
the sample size of the trial, the number of study arms, and 
the types of interventions used in the trial. Finally, we 
reviewed the trial registry entry to obtain details about the 
timing of registration and the timing of study commence-
ment. RCTs that were registered before or within one 
month of study commencement were coded as prospec-
tively registered to be consistent with the Food and Drug 
Administration requirement on trial registration. Where 
only the month and year of study commencement were 
provided in the trial registry without listing the specific 
day, we assumed it was the first day of the month. All 
remaining RCTs that were registered with a trial registra-
tion number were coded as retrospectively registered.
Trials were coded as having positive study findings if 
an investigator defined primary outcome in the trial 
publication was statistically significant (effect estimate 
with confidence interval that does not cross the line of 
no effect or a P<0.05) in favour of the experimental 
intervention. If studies were non-inferiority trials, they 
were coded as having positive study findings if there 
was no statistically significant difference between the 
experimental and control interventions. If studies had 
multiple primary outcomes, we assessed each outcome 
and if at least one was statistically significant, we coded 
the study as having positive study findings. If no pri-
mary outcome was reported, we assessed the main out-
come that was emphasised in the abstract and results 
for statistical significance. Classification of trial regis-
tration status and study outcomes was performed sepa-
rately in two independent phases of data extraction.
Our primary analysis was to assess an association 
between trial registration and positive study findings. 
We assessed trial registration as an overall exposure and 
stratified by prospective and retrospective registration. 
We additionally assessed whether the association 
between reporting of trial registration and positive study 
findings varied by funding source (industry versus 
non-industry funding) through a test for interaction.
Data analysis
We generated summary statistics for the general charac-
teristics and methodological quality of RCTs included in 
our study. The χ2 test was used to compare categorical 
variables and the t test or Wilcoxon rank sum test was 
used to compare continuous variables. Although we ini-
tially used logistic regression, the percentage of RCTs 
with positive study findings was more than 50%. It is 
therefore likely that the odds ratio will overestimate the 
box 1: Definitions used to assess methodological quality of publications of rCts
primary outcome
Primary outcome defined explicitly or an outcome used in sample size calculation; or 
a main outcome described explicitly in primary study objectives: yes or no
sample size calculation
Sample size calculation stated to have been undertaken: yes or no
random sequence generation
Method used to allocate participants to study groups: computer, random number 
table, coin toss, not reported or inadequate, other
allocation concealment
Method used to prevent the individual enrolling participants from knowing or 
predicting the allocation sequence in advance: envelope, central, pharmacy, not 
reported or inadequate, other
blinding, how?
Method used to prevent participants, caregivers, investigators, or outcomes 
assessors from knowing the intervention a participant received. Trial is unblinded if 
explicitly stated as such or blinding not possible: blinded, details given, blinded, no 
details, unblinded, or not reported
blinding, who?
Reported, details given (eg, patient, caregiver), reported, no details given (eg, double 
blinded), unblinded, or unclear
attrition
Loss to follow-up reported for each group: yes, details given, yes, details not given, or no
intention to treat
Reported as having been analysed in their assigned groups: intention to treat, or no 
intention to treat
the bmj | BMJ 2017;356:j917 | doi: 10.1136/BMJ.j917
RESEARCH
3
risk ratio and overestimate the association between trial 
registration and positive study findings. We therefore 
used multivariable Poisson regression with robust stan-
dard errors to obtain risk ratios and to assess the associ-
ation between reporting of trial registration and positive 
findings. The Poisson regression model was adjusted for 
variables that have been shown to affect study find-
ings,11 12 including study sample size (continuous) and 
funding source (industry funded versus non-industry 
funded versus unclear), random sequence generation 
(yes versus not reported), allocation  concealment (yes 
versus not reported), type of intervention (pharmacolog-
ical versus non-pharmacological), and number of cen-
tres (single versus multiple versus unclear). To assess for 
consistency of the association by funding source, we 
tested for an interaction between trial registration and 
study funding (non-industry funded versus industry 
funded). If a statistically significant interaction was 
found, we examined the estimates for the association 
between reporting of trial registration and positive study 
findings within the relevant subgroups of funding.
In a sensitivity analysis, we included trials with 
unclear funding in the regression model to test for an 
interaction by funding source. We also excluded trials 
that were not registered in a WHO primary registry. P 
values less than 0.05 were considered statistically sig-
nificant. Statistical analyses were conducted with R Sta-
tistical Software (3.2.0) and Stata 14.
patient involvement
No patients were involved in setting the research ques-
tion or the outcome measures, nor were they involved in 
developing plans for design or implementation of the 
study. No patients were asked to advise on  interpretation 
or writing up of results. There are no plans to dissemi-
nate the results of the research to study participants or 
the relevant patient community.
Results
general characteristics and reporting of 
methodological items in the overall cohort
The search yielded 4190 abstracts, of which 1676 were 
included in the full text review (fig 1 ). Of these, 1111 full 
text articles met the inclusion criteria. Eleven articles 
included two independent trials, thereby increasing the 
total number of randomised controlled trials (RCTs) to 
1122. Three hundred trials (26.7%) were single centre, 
298 (26.6%) were multicentre, and 524 (46.7%) had an 
unclear number of centres (table 1 ). With respect to 
design characteristics, 953 trials (84.9%) were parallel 
group studies and 892 (79.5%) had two intervention 
arms (table 1 ). The median sample size was 86 
 (interquartile range 43-193) and 513 trials (45.7%) were 
non-industry funded, compared with 302 trials (26.9%) 
and 307 trials (27.4%) that were solely or partly industry 
funded or had unclear funding, respectively (table 1). 
The RCTs were published in 543 unique journals. 
The median impact factor was 3 (interquartile range 2-5) 
and only 34 of 1122 (3.0%) were published in general 
 medical journals (New England Journal of Medicine, 
Lancet, Journal of the American Medical Association, 
The BMJ, Annals of Internal Medicine, and PloS Medi-
cine). Two hundred and sixty eight RCTs (23.9%) were 
published in journals endorsed by the International 
Committee of Medical Journal Editors (ICMJE) (table 1).
Sample size calculations were reported in 622 trial 
publications (55.4%) and the primary outcome was 
defined in 779 trials (69.4%) (table 2 ). Only 567 trial pub-
lications (50.5%) and 391 (34.8%) trial publications 
reported the method for random sequence generation 
and allocation concealment, respectively (table 2 ). Eight 
hundred and sixty two trial publications (76.8%) and 
858 trial publications (76.5%) reported the method used 
for blinding and who was blinded, respectively (table 2 ). 
Finally, loss to follow-up for each study group was 
reported in 745 trials publications (66.4%) and an inten-
tion to treat analysis was reported in 312 trial publica-
tions (27.8%, table 2).
Characteristics of trials based on registration
Overall, 529 RCTs (47.1%) were not reported as regis-
tered in the publication and 593 RCTs (52.9%) were reg-
istered. Of the registered trials, 222 (37.4%) were 
registered prospectively and 373 (62.9%) retrospectively.
Trials that were registered were more likely to be mul-
ticentre, have a larger sample size, and be industry 
funded (table 1 ). They were also more likely to be pub-
lished in general medical journals and in journals 
endorsed by the ICMJE (table 1 ). Trials that were regis-
tered were more likely to specify a primary outcome and 
provide details about sample size calculations, random 
sequence generation, allocation  concealment, 
blinding, and attrition (table 2 ). They were also more 
likely to report an intention to treat analysis (table 2).
positive study findings
Among the 529 RCTs that were not registered, 322 
(60.9%) reported a positive study finding compared 
with 309 of the 593 RCTs (52.1%) that were registered.
Abstracts screened (n=4190)
Full text papers reviewed (n=1676)
Full text papers eligible for inclusion (n=1111)
  Studies included (n=11; 2 trials)
Randomised trials included (n=1122):
  Reported in English (n=1085)
  Reported in a non-English language (n=37)
Abstracts excluded (n=2514):
  Not randomised (n=1511)
  Secondary publications (n=269)
  Protocols (n=87)
  Non-health interventions (n=28)
  Reviews/comments (n=414)
  Meta-analyses (n=111)
  Non-human participants (n=94)
Full text papers excluded (n=565):
  Not randomised (n=111)
  Secondary publications (n=140)
  Editorials/commentaries (n=20)
  Non-health interventions (n=57)
  Reviews (n=17)
  Diagnostic test studies (n=2)
  Trial protocol (n=1)
  Pharmacokinetic/physiology (n=212)
  Not translated by author (AJH) (n=5)
Fig 1 | identification of 
included studies
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In an unadjusted analysis, trials that were registered 
were less likely to report a positive study finding (risk 
ratio 0.86, 95% confidence interval 0.77 to 0.95). The 
association was marginally statistically significant after 
multivariable adjustment (adjusted risk ratio 0.87, 0.78 to 
0.98, fig 2  and table 1  in the web appendix). Similar find-
ings were obtained when the RCTs that were registered 
were stratified into retrospectively and  prospectively reg-
istered studies (fig 2  and table 1 in the web appendix).
The interaction between trial registration and funding 
source was marginally significant (P interaction=0.046 
for non-industry versus solely or partly industry funded 
studies, table 3 ). Among non-industry funded studies, 
registered trials (overall) were less likely to report posi-
tive study findings compared with trials that were not 
registered (adjusted risk ratio 0.75, 0.63 to 0.89, table 1  in 
the web appendix). In contrast, an association between 
trial registration and positive study findings was not 
found among industry funded studies (adjusted risk 
ratio 1.03, 0.79 to 1.36 for overall registration, table 1  in 
the web appendix). The test for interaction was not sta-
tistically significant when studies were stratified by pro-
spective and retrospective registration (table 3).
sensitivity analysis
If trials with unclear funding were included in the 
regression model to test whether the association 
between trial registration and positive study findings 
varied between non-industry and industry funded tri-
als, the P value for the test of interaction was 0.053 and 
strata specific relative risk estimates were unchanged. 
The interaction terms for trial registration and positive 
study findings were statistically significant for non-in-
dustry funded studies versus studies with unclear fund-
ing (P interaction=0.005). However, this was not a 
prespecified subgroup comparison and was not exam-
ined further. Five trials were registered but not in a 
WHO primary registry (eg, Hong Kong University Clini-
cal Trial Registry). When these trials were excluded, our 
overall results were unchanged and the test for interac-
tion comparing non-industry and industry funded trials 
was not significant (P interaction=0.05) and strata spe-
cific relative risk estimates were unchanged.
discussion
In an analysis of 1122 published randomised controlled 
trials (RCTs), there was little evidence of a difference in 
positive study findings between registered and non-reg-
istered clinical trials, nor when trials were stratified as 
prospectively registered and retrospectively registered. 
Subgroup analyses were inconclusive as to whether the 
association between trial registration and positive 
study findings varied between non-industry funded and 
industry funded trials.
table 1 | general characteristics of included studies
Characteristics
Overall 
(n=1122) 
(no, col %)
not 
registered 
(n=529) 
(no, row %)
registered 
(n=593) 
(no, row %) p value
prospectively 
registered 
(n=220) (no, 
row %)*
retrospectively 
registered 
(n=373) (no, 
row %)* p value†
Study centres:
 Single 300 (26.7) 157 (52.3) 143 (47.7)
<0.001
43 (14.3) 100 (33.3)
<0.001 Multiple 298 (26.6) 65 (21.8) 233 (78.2) 111 (37.3) 122 (40.9)
 Unclear 524 (46.7) 307 (58.6) 217 (41.4) 66 (12.6) 151 (28.8)
Design:
 Parallel group 953 (84.9) 442 (46.4) 511 (53.6)
0.24
188 (19.7) 323 (33.9)
0.36
 Cluster 31 (2.8) 14 (45.2) 17 (54.8) 4 (12.9) 13 (41.9)
 Crossover 98 (8.7) 48 (49.0) 50 (51.0) 22 (22.5) 28 (28.6)
 Other 40 (3.6) 25 (62.5) 15 (37.5) 6 (15.0) 9 (22.5)
No of arms:
 2 892 (79.5) 424 (47.5) 468 (52.5)
0.03
170 (19.1) 298 (33.4)
0.08
 3 146 (13.0) 65 (44.5) 81 (55.5) 35 (24.0) 46 (31.5)
 4 61 (5.4) 35 (57.4) 26 (42.6) 10 (16.4) 16 (26.2)
 >4 23 (2.1) 5 (21.7) 18 (78.3) 5 (21.7) 13 (56.5)
Median (interquartile range) sample size (No of randomised participants) 86 (43-193) 66 (39-144) 105 (51-254) <0.001 117 (59-296) 100 (48-232) <0.001
Funding:
 Non-industry 513 (45.7) 249 (48.5) 264 (51.5)
<0.001
79 (15.4) 185 (36.1)
<0.001 Solely or partly industry 302 (26.9) 65 (21.5) 237 (78.5) 117 (38.7) 120 (39.7)
 Unclear 307 (27.4) 215 (70.0) 92 (30.0) 24 (7.8) 67 (22.2)
Journal specific variables
Median (interquartile range) impact factor 3 (2-5) 2 (1-3) 4 (2-6) <0.001 5 (3-8) 3 (2-5) <0.001
General medical journals*:
 Yes 34 (3.0) 1 (3.0) 33 (97.1)
<0.001
21 (61.8) 12 (35.3)
<0.001
 No 1088 (97.0) 528 (48.5) 560 (51.5) 199 (18.3) 361 (33.2)
ICMJE endorsed:
 Yes 268 (23.9) 84 (31.3) 184 (68.7)
<0.001
81 (30.2) 103 (38.4)
<0.001
 No 854 (76.1) 445 (52.1) 409 (47.9) 139 (16.3) 270 (31.6)
ICMJE=International Committee of Medical Journal Editors.
*Percentages obtained from 3×2 table including trials prospectively registered, retrospectively registered, and not registered.
†Generated from χ2 test comparing proportion of trials prospectively registered, retrospectively registered, and not registered.
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strengths and weaknesses of this study
The major strength of our study is its large sample size, 
which allowed us to examine trial registration in import-
ant subgroups. We also examined all trials published 
and indexed in PubMed within a one month period, 
which enhances the generalisability of our findings. 
Our study also has limitations. Firstly, by sampling a 
one month period in PubMed, we inherently included 
trials across the spectrum of medical journals. There-
fore, the quality of reporting in several trials was poor. 
However, we accounted for differences in the quality of 
reporting in registered and non-registered trials through 
the use of multivariable regression. Secondly, 25% of 
the studies included in our analysis had unclear fund-
ing sources. This limited the number of non-industry 
and industry funded trials we were able to identify in 
our analysis and contributed to imprecise relative risk 
estimates. None the less, the sample sizes of our sub-
groups were comparable to, if not larger than, the total 
number of trials in each of the previous methodological 
studies examining whether trial registration was asso-
ciated with positive study findings.4 5 13 Thirdly, we ana-
lysed trials published in 2012 and it is likely that many 
of these studies were initiated well before then. Trial 
registration practices and patterns may have changed 
over the time that trials in our analysis were initiated 
and conducted. However, trial registration is now prev-
alent and it would be more difficult to assess the associ-
ation between trial registration and positive study 
findings with a more contemporary cohort of clinical 
table 2 | methodological items of included studies
items
Overall 
(n=1122) 
(no, col %)
not registered 
(n=529) (no, row %)
registered 
(n=593) 
(no, row %) p value
prospectively 
registered (n=220) 
(no, row %)*
retrospectively 
r (n=373)  
(no, row %)* p value†
Defined primary outcome reported:
 Yes 779 (69.4) 256 (32.9) 523 (67.1)
<0.001
200 (25.7) 323 (41.5)
<0.001
 No 343 (30.6) 273 (79.6) 70 (20.4) 20 (5.8) 50 (14.6)
Sample size calculation reported:
 Yes 622 (55.4) 195 (31.4) 427 (68.6)
<0.001
159 (25.6) 268 (43.1)
<0.001
 No 500 (44.6) 334 (66.8) 166 (33.2) 61 (12.2) 105 (21.0)
Random sequence generation:
 Computer 456 (40.6) 169 (37.1) 287 (62.9)
<0.001
109 (23.9) 178 (39.0)
<0.001
 Random number table 69 (6.2) 44 (63.8) 25 (36.2) 3 (4.4) 22 (31.9)
 Not reported or inadequate 555 (49.5) 288 (51.9) 267 (48.1) 103 (18.6) 162 (29.6)
 Other 42 (3.7) 28 (66.7) 14 (33.3) 5 (11.9) 9 (21.4)
Allocation concealment:
 Envelope 209 (18.6) 91 (43.5) 118 (56.5)
<0.001
24 (11.5) 94 (45.0)
<0.001
 Central 100 (8.9) 12 (12.0) 88 (88.0) 48 (48.0) 40 (40.0)
 Pharmacy 44 (3.9) 9 (20.5) 35 (79.5) 18 (40.9) 17 (38.6)
 Not reported or inadequate 731 (65.2) 402 (55.0) 329 (45.0) 125 (17.1) 204 (27.9)
 Other 38 (3.4) 15 (39.5) 23 (60.5) 5 (13.2) 18 (47.4)
Blinding, how?:
 Blinded, details given 265 (23.6) 94 (35.5) 171 (64.5)
<0.001
73 (27.6) 98 (37.0)
<0.001
 Blinded, no details given 416 (37.1) 172 (41.5) 244 (58.7) 97 (23.3) 147 (35.3)
 Unblinded 181 (16.1) 94 (51.9) 87 (48.1) 20 (11.1) 67 (37.0)
 Not reported 260 (23.2) 169 (65.0) 91 (35.0) 30 (11.5) 61 (23.5)
Blinding, who?:
 Reported, details given 507 (45.2) 210 (41.4) 297 (58.6)
<0.001
115 (22.7) 182 (35.9)
<0.001
 Reported, no details given 170 (15.2) 52 (30.6) 118 (69.4) 55 (32.4) 63 (37.1)
 Unblinded 181 (16.1) 94 (51.9) 87 (48.1) 20 (11.1) 67 (37.0)
 Unclear 264 (23.5) 173 (65.5) 91 (34.5) 30 (11.4) 61 (23.1)
Attrition:
 Yes, details given 625 (55.7) 202 (32.3) 423 (67.7)
<0.001
168 (26.9) 255 (40.8)
<0.001 Yes, details not given 120 (10.7) 57 (47.5) 63 (52.5) 18 (15.0) 45 (37.5)
 No 377 (33.6) 270 (71.6) 107 (28.4) 34 (9.0) 73 (19.4)
Intention to treat:
 Intention to treat 312 (27.8) 74 (23.7) 238 (76.3)
<0.001
87 (27.9) 151 (48.4)
<0.001
 No intention to treat 810 (72.2) 455 (56.2) 355 (43.8) 133 (16.4) 222 (27.4)
*Percentages from 3×2 table including trials prospectively registered, retrospectively registered, and not registered.
†Generated from χ2 test comparing proportion of trials prospectively registered, retrospectively registered, and not registered.
Overall
Prospectively registered
Retrospectively registered
0.87 (0.78 to 0.98)
0.87 (0.74 to 1.02)
0.88 (0.78 to 1.00)
0.3 0.5 1 2 3
Group
Positive findings
not favoured in
registered trials
Positive findings
favoured in
registered trials
Adjusted risk ratio
(95% CI)
Adjusted risk ratio
(95% CI)
309/593 (52.1)
115/220 (52.3)
194/373 (52.0)
Registered
322/529 (60.9)
322/529 (60.9)
322/529 (60.9)
Not registered
RCTs with positive
findings/total RCTs (%)
Fig 2 | association between reporting of trial registration and positive study findings. 
rCt=randomised controlled trial
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trials. Finally, our analysis relied on reported informa-
tion in trial publications and it is unclear whether this 
is reflective of the prespecified trial design and conduct. 
We were also unable to account for unpublished stud-
ies, which may differ from the published literature. 
Future studies should focus on gaining access to clini-
cal trial protocols and comparing the rate of positive 
primary outcomes in registered and non-registered clin-
ical trials.
strengths and weaknesses in relation to other 
studies
Trial registration was introduced as a method to improve 
transparency and accountability in research, yet evi-
dence as to whether trials that are registered are less 
likely to report positive study findings is limited. Exist-
ing studies on the association between trial registration 
and positive study findings are restricted to a small cross 
sectional study of cardiovascular trials and a meta-epi-
demiological study. In neither study was the analysis 
examined based on the funding source of the trial.
By examining a large unselected group of trials, irre-
spective of medical specialty, journal, intervention 
type, or disease type, we found little evidence of an 
association between trial registration and positive 
study findings in the overall analysis. Firstly, RCTs that 
were registered were less likely to report positive study 
findings compared with RCTs that were not registered, 
but the risk ratio estimates were modest and the 95% 
confidence intervals were close to the line of no effect. 
When stratified by the timing of trial registration, there 
was little evidence of a difference in positive study find-
ings between prospectively registered trials and 
non-registered trials, but the association for retrospec-
tive registration was statistically significant. We noted 
that the association between trial registration and pos-
itive study findings may vary between non-industry and 
industry funded trials. Although the test for interaction 
was statistically significant, the relative risk estimates 
were imprecise therefore limiting any clear conclusions.
In addition to the limited evidence for an association 
between trial registration and study findings, the qual-
ity of reporting in the trials included in our analysis was 
poor. In particular, important methodological items 
such as the method for random sequence generation 
and allocation concealment were infrequently reported 
in published trials. This limits the utility of the RCTs for 
policy makers and systematic reviewers. Accordingly, 
there must be ongoing efforts to improve the quality of 
reporting in published trials and to increase the propor-
tion of journals that adopt and adhere to reporting 
guidelines such as CONSORT (Consolidated Standards 
of Reporting Trials).14 These efforts are needed along-
side initiatives to increase trial registration.
implications for clinicians, policy makers, and 
future research
Our findings show that among all trials, there was little 
evidence of a difference in the frequency of positive 
study findings between registered and non-registered 
trials. These findings are important given the efforts of t
ab
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the WHO and ICMJE and the financial investment of 
research regulatory authorities to provide a platform for 
trial registration and to promote policies that support 
trial registration. Our findings are also important for 
researchers and other consumers of the scientific litera-
ture who may assume that trial registration alone 
increases accountability for the accurate reporting of 
trial results.
There may be multiple reasons for our results. Firstly, 
it has yet to be determined whether the information 
reported in trial registries is an accurate reflection of the 
trial protocol that was approved by the research ethics 
committee.15 It may be that study outcomes are not fully 
specified in the trial registry and, for instance, import-
ant details about the time point for analysis or the 
method of analysis may be missing in the registry. Dis-
crepancies between the trial registry and study protocol 
reduce the accountability to conduct and report the 
study in accordance with what was planned.
Secondly, it may be that trials are registered but the 
trial registration number is omitted from the published 
article during submission to the journal or after peer 
review. In our study, 15% of trials were not reported as 
registered but were identified in a search of trial regis-
tries. The omission of the trial registration number in 
the published article also reduces the accountability 
that is inherent in trial registration. Finally, it may be 
that comparisons between the trial registry and RCTs 
are not routinely performed by peer reviewers or jour-
nal editors. Without these comparisons the utility of 
trial registration may be easily diluted by outcome 
switching.16  Indeed, investigators recently found dis-
crepancies between trial registries and published arti-
cles and these differences favour statistically significant 
results.17
Registration of clinical trials is only the first step in 
improving the accountability in the reporting of 
research. It is necessary for journal editors, reviewers of 
journal articles, and researchers to report the trial regis-
tration number in the published article and to compare 
the results in the published article to that of the trial 
registry entry. These efforts ensure the benefits of trial 
registration are not undermined.16
Conclusion
Taken together, in a large study of published RCTs, we 
did not observe an association between trial registra-
tion and positive study findings. Further efforts are 
needed to ensure that all trials are registered and the 
details given in the registry are reported in the pub-
lished article.
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